文献速递肿瘤 PET/CT

复发性前列腺癌放射性示踪剂诊断性能比较:系统综述与网络荟萃分析

Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-02-06

除18F-PSMA-1007外,常用PSMA示踪剂间检出率差异不大,但均明显优于胆碱和氟昔洛韦。目前证据不足以在四种常规PSMA配体中优选一种。

要点

  • PSMA示踪剂检出率明显优于胆碱和氟昔洛韦。
  • 常用PSMA示踪剂间除18F-PSMA-1007外差异不大。
  • 证据不足以在四种常规PSMA配体中优选一种。

核心结论

  • PSMA与胆碱示踪剂在患者水平检出率上存在差异,但证据不足以在四种常规PSMA配体中优选一种。

研究设计与样本

  • 系统检索PUBMED、EMBASE及EU和NIH试验数据库,无日期和语言限制,纳入13种主要示踪剂的比较影像研究。
  • 采用QUADAS-2评估偏倚风险,使用马尔可夫链蒙特卡洛贝叶斯网络荟萃分析估计检出率比值比。

主要发现

  • 多数研究被判定存在发表偏倚风险。
  • 除18F-PSMA-1007外,三种最常用PSMA示踪剂(68Ga-PSMA-11、18F-PSMA-1007、18F-DCFPyl)间检出率差异不大。
  • PSMA示踪剂在 derived network 中明显优于胆碱和氟昔洛韦。

临床怎么用

  • 网络荟萃分析结果可用于指导未来临床试验设计,并提示当前证据薄弱领域。
  • 选择示踪剂时需注意缺乏诊断准确性报告可能偏袒低特异性示踪剂。

局限性

  • 多数研究存在发表偏倚风险。
  • 缺乏诊断准确性报告,分析仅限检出率可能偏袒低特异性示踪剂。
  • 证据基础有限,不足以在四种常规PSMA配体间优选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Many radiotracers are currently available for the detection of recurrent prostate cancer (rPC), yet many have not been compared head-to-head in comparative imaging studies. There is therefore an unmet need for evidence synthesis to guide evidence-based decisions in the selection of radiotracers. The objective of this study was therefore to assess the detection rate of various radiotracers for the rPC. METHODS: The PUBMED, EMBASE, and the EU and NIH trials databases were searched without date or language restriction for comparative imaging tracers for 13 radiotracers of principal interest. Key search terms included 18F-PSMA-1007, 18F-DCPFyl, 68Ga-PSMA-11, 18F-PSMA-11, 68Ga-PSMA-I&T, 68Ga-THP-PSMA, 64Cu-PSMA-617, 18F-JK-PSMA-7, 18F-Fluciclovine, 18F-FABC, 18F-Choline, 11C-Choline, and 68Ga-RM2. Studies reporting comparative imaging data in humans in rPC were selected. Single armed studies and matched pair analyses were excluded. Twelve studies with eight radiotracers were eligible for inclusion. Two independent reviewers screened all studies (using the PRISMA-NMA statement) for inclusion criteria, extracted data, and assessed risk of bias (using the QUADAS-2 tool). A network meta-analysis was performed using Markov-Chain Monte Carlo Bayesian analysis to obtain estimated detection rate odds ratios for each tracer combination. RESULTS: A majority of studies were judged to be at risk of publication bias. With the exception of 18F-PSMA-1007, little difference in terms of detection rate was revealed between the three most commonly used PSMA-radiotracers (68Ga-PSMA-11, 18F-PSMA-1007, 18F-DCFPyl), which in turn showed clear superiority to choline and fluciclovine using the derived network. CONCLUSION: Differences in patient-level detection rates were observed between PSMA- and choline-radiotracers. However, there is currently insufficient evidence to favour one of the four routinely used PSMA-radioligands (PSMA-11, PSMA-1007, PSMA-I&T, and DCFPyl) over another owing to the limited evidence base and risk of publication bias revealed by our systematic review. A further limitation was lack of reporting on diagnostic accuracy, which might favour radiotracers with low specificity in an analysis restricted only to detection rate. The NMA derived can be used to inform the design of future clinical trials and highlight areas where current evidence is weak.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Alberts IL, Seide SE, Mingels C, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021. PMID: 33550425. doi:10.1007/s00259-021-05210-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。